Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;131(12):1481-1494.
doi: 10.1007/s00702-024-02799-7. Epub 2024 Jun 21.

Anticholinergic drugs for parkinsonism and other movement disorders

Affiliations
Review

Anticholinergic drugs for parkinsonism and other movement disorders

Peter A LeWitt et al. J Neural Transm (Vienna). 2024 Dec.

Abstract

Anticholinergic (AC) drugs, a medication class that acts by blocking nicotinic and muscarinic acetylcholine receptors, were first utilized for therapeutic purposes in the mid-19th century. Initial applications were as symptomatic therapy for Parkinson disease (PD), a practice continuing to the present. Initially, the AC drugs used were naturally-occurring plant compounds. Synthetic AC drugs were developed in the late 1940s and predominated in neurological therapeutics. Until the advent of pharmaceuticals acting upon striatal dopaminergic motor pathways, AC drugs provided the only effective means for lessening tremors and other clinical problems of the PD patient. However, because dopaminergic compounds are so effective at meeting the needs of the typical PD patient, AC medications are far less utilized by clinicians today. In recent years, there has been only a few investigations of AC drugs as neurological treatments. This review will revisit the clinical landscape of AC pharmacology and application for movement disorders along with recent research in search of improving therapeutics with AC drugs.

Keywords: Acetylcholine; Anticholinergic; Dystonia; Movement disorders; Parkinson disease.

PubMed Disclaimer

Similar articles

References

    1. Agate FJ Jr, Doshay LJ, Curtis FK (1956) Quantitative measurement of therapy in paralysis agitans. JAMA 160:352–354 - DOI
    1. Albin RL, Cross D, Cornblath WT et al (2003) Diminished striatal [123I]iodobenzovesamicol binding in idiopathic cervical dystonia. Ann Neurol 53:528–532 - PubMed - DOI
    1. Anderson E, Nutt J (2011) The long-duration response to levodopa: phenomenology, potential mechanisms, and clinical implications. Parkinsonism Relat Disord 7:589–592
    1. Ayd FJ (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175:–1060
    1. Bergman H, Soares-Weiser K (2018) Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 17(1):CD000204

MeSH terms

Substances

LinkOut - more resources